Climb Bio (CLYM) Competitors $1.94 +0.06 (+3.19%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLYM vs. FULC, OCGN, ESPR, ORGO, ADCT, INBX, CYRX, SLDB, RAPT, and ATXSShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Fulcrum Therapeutics (FULC), Ocugen (OCGN), Esperion Therapeutics (ESPR), Organogenesis (ORGO), ADC Therapeutics (ADCT), Inhibrx Biosciences (INBX), CryoPort (CYRX), Solid Biosciences (SLDB), Rapt Therapeutics (RAPT), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Fulcrum Therapeutics Ocugen Esperion Therapeutics Organogenesis ADC Therapeutics Inhibrx Biosciences CryoPort Solid Biosciences Rapt Therapeutics Astria Therapeutics Climb Bio (NASDAQ:CLYM) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings. Does the media refer more to CLYM or FULC? In the previous week, Climb Bio had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 11 mentions for Fulcrum Therapeutics. Climb Bio's average media sentiment score of 0.98 beat Fulcrum Therapeutics' score of 0.56 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in CLYM or FULC? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 0.8% of Climb Bio shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CLYM or FULC more profitable? Climb Bio's return on equity of -23.10% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -23.10% -22.47% Fulcrum Therapeutics N/A -31.05%-28.96% Which has higher valuation and earnings, CLYM or FULC? Fulcrum Therapeutics has higher revenue and earnings than Climb Bio. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$0.70-2.77Fulcrum Therapeutics$80M6.52-$9.73M-$1.22-7.90 Do analysts rate CLYM or FULC? Climb Bio presently has a consensus target price of $9.20, indicating a potential upside of 374.23%. Fulcrum Therapeutics has a consensus target price of $9.60, indicating a potential downside of 0.41%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Fulcrum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more risk & volatility, CLYM or FULC? Climb Bio has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. SummaryClimb Bio beats Fulcrum Therapeutics on 10 of the 15 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.40M$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-2.7722.7785.3627.36Price / SalesN/A465.72601.96132.92Price / CashN/A46.7037.4661.86Price / Book0.6210.5512.426.81Net Income-$73.90M-$52.58M$3.32B$276.80M7 Day Performance2.65%0.09%0.57%0.42%1 Month Performance-3.48%15.61%10.52%7.86%1 Year PerformanceN/A15.13%72.99%41.24% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio4.1357 of 5 stars$1.94+3.2%$9.20+374.2%N/A$127.40MN/A-2.779Trending NewsAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics0.8476 of 5 stars$9.58-0.5%$9.60+0.3%+163.4%$522.10MN/A-7.91100News CoverageOCGNOcugen1.4588 of 5 stars$1.78-3.0%$6.00+238.0%+76.3%$521.76M$4.75M-8.9280ESPREsperion Therapeutics3.7667 of 5 stars$2.53+3.1%$7.00+177.2%+18.3%$517.16M$332.31M-5.23200ORGOOrganogenesis3.736 of 5 stars$4.00-3.3%$7.33+83.6%+27.2%$516.57M$429.31M-29.08950Gap DownADCTADC Therapeutics2.5018 of 5 stars$4.52-1.4%$7.75+71.3%+40.2%$511.65M$70.84M-2.90310INBXInhibrx Biosciences1.7027 of 5 stars$34.26+1.9%N/A+128.3%$501.51M$1.40M-3.27166High Trading VolumeCYRXCryoPort3.8346 of 5 stars$9.89-0.6%$12.56+27.0%+35.5%$498.20M$228.38M7.481,186SLDBSolid Biosciences2.7791 of 5 stars$6.30-1.6%$15.00+138.2%-4.7%$497.58MN/A-2.28100RAPTRapt Therapeutics3.3605 of 5 stars$29.83+1.3%$23.50-21.2%+86.7%$493.33MN/A-2.1180Analyst ForecastAnalyst RevisionATXSAstria Therapeutics2.1855 of 5 stars$8.35-1.2%$29.50+253.5%+3.7%$479.70MN/A-4.2330Trending NewsAnalyst DowngradeGap Up Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Ocugen Competitors Esperion Therapeutics Competitors Organogenesis Competitors ADC Therapeutics Competitors Inhibrx Biosciences Competitors CryoPort Competitors Solid Biosciences Competitors Rapt Therapeutics Competitors Astria Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
